Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

BRECISE Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement

Coordinator
South East Technological University, Ireland
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€13.6m
Total cost
€23.0m
Partners
30 organisations in 14 countries
Type
Research and Innovation Action
Grant agreement
101194784

What the project is doing

In the project's own words, from its summary on CORDIS.

BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility.

This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology.

By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care. The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects.

The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.

Topics

Who is involved

OrganisationCityCountryRole
South East Technological UniversityWaterfordIrelandCoordinator
European Alliance for Personalised Medicine ASBLBruxelles / BrusselBelgiumParticipant
Ohmx.bioGentBelgiumParticipant
Novigenix SAEpalingesSwitzerlandAssociatedpartner
Pharmaledger AssociationBaselSwitzerlandAssociatedpartner
Udg AllianceLausanneSwitzerlandAssociatedpartner
Bridg OuTallinEstoniaParticipant
Elliniki Omospondia Karkinou Ell OkAthinaGreeceParticipant
Atrys Health SAMadridSpainParticipant
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainThird party
Predictby Research and Consulting S.l.BarcelonaSpainParticipant
Servicio Andaluz De SaludSevillaSpainParticipant
Universidad Complutense De MadridMadridSpainParticipant
Biocomputing Platforms Ltd OyEspooFinlandParticipant
Bc PlatformsToulouseFranceAssociatedpartner
Mutualite Fonction Publique Action Sante SocialParisFranceParticipant
Genomate Health Hungary KftBudapestHungaryParticipant
Agenzia Di Tutela Della Salute Della BrianzaMonzaItalyParticipant
Associazione Italiana Malati Di Cancro, Parenti E AmiciRomaItalyParticipant
Dedalus Italia S.p.a.FirenzeItalyParticipant
Uab Cureline BalticVilniusLithuaniaParticipant
3d-Pharmxchange BVTilburgNetherlandsParticipant
Crown Bioscience Netherlands BVLeidenNetherlandsParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Hub Organoids BVUtrechtNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Region StockholmStockholmSwedenParticipant
Vastra GotalandsregionenVanersborgSwedenParticipant
Bioclavis LimitedClydebankUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI